Pharmacokinetics and Adverse Reactions of Various Dosage Regimens of Intravenous Pentamidine in the Treatment of HIV-Associated Pneumocystis carinii Pneumonia
Dr Keikawus, N. Arastéh,Hans, F. Vöhringer,Michael, M. Stratmann…
Clinical Drug Investigation 6(4): 207-217
1993
ISSN/ISBN: 1173-2563 DOI: 10.1007/bf03259245
Accession: 062326196
PDF emailed within 0-6 h: $19.90
Related References
Arasteh, K.N.; Voehringer, H.F.; Stratmann, M.M.; Tschechne, B.K.; Heise, W.S.; L'age, M.P. 1993: Pharmacokinetics and adverse reactions of various dosage regimens of intravenous pentamidine in the treatment of HIV-associated Pneumocystis carinii pneumonia Drug Investigation 6(4): 207-217Manova, M.G.; Kostadinova, I.I. 2009: Adverse drug reactions after 24-month treatment with two-dosage regimens of betaferon in patients with multiple sclerosis Folia Medica 51(3): 31-36
Gustafsson, L.L.; Bronner, U.; Rombo, L.; Doua, F.; Ericsson, O.; Miezan, T. 1995: Multiple-dose pharmacokinetics and adverse reactions of pentamidine in patients with African sleeping sickness Therapie (Paris) 1995(Suppl ): 474
Bronner, U.; Gustafsson, L.L.; Doua, F.; Ericsson, O.; Miézan, T.; Rais, M.; Rombo, L. 1995: Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with Trypanosoma gambiense sleeping sickness British Journal of Clinical Pharmacology 39(3): 289-295
Reilly, C.S.; Wood, A.J.; Wood, M. 1985: Variability of fentanyl pharmacokinetics in man. Computer predicted plasma concentrations for three intravenous dosage regimens Anaesthesia 40(9): 837-843
Ooi, M.How.; Ngu, S.Jiat.; Chor, Y.Kee.; Li, J.; Landersdorfer, C.B.; Nation, R.L. 2019: Population Pharmacokinetics of Intravenous Colistin in Pediatric Patients: Implications for the Selection of Dosage Regimens Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 69(11): 1962-1968
Sandri, A.M.; Landersdorfer, C.B.; Jacob, J.; Boniatti, Márcio.M.; Dalarosa, M.G.; Falci, D.R.; Behle, Tá.F.; Bordinhão, R.C.; Wang, J.; Forrest, A.; Nation, R.L.; Li, J.; Zavascki, A.P. 2013: Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 57(4): 524-531
Riviere, J.E.; Frazier, D.L.; Tippitt, W.L. 1988: Pharmacokinetic estimation for therapeutic dosage regimens (PETDR)--a software program designed to determine intravenous drug dosage regimens for veterinary applications Journal of Veterinary Pharmacology and Therapeutics 11(4): 390-396
Thønnings, S.; Jensen, K.S.; Nielsen, N.B.; Skjønnemand, M.; Hansen, D.S.; Lange, K.H.W.; Frimodt-Møller, N. 2020: Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers Journal of Medical Microbiology 69(3): 387-395
Balslev, U.; Nielsen, T.L. 1992: Adverse effects associated with intravenous pentamidine isethionate as treatment of Pneumocystis carinii pneumonia in AIDS patients Danish Medical Bulletin 39(4): 366-368
Kronawitter, U.; Bogner, J.R.; Goebel, F.D. 1992: Low incidence of Pneumocystis cariniipneumonia in Hiv patients receiving 300 mg pentamidine aerosol every 2 weeks Journal of Molecular Medicine 70(12): 1089-1091
O'Brien, J.G.; Dong, B.J.; Coleman, R.L.; Gee, L.; Balano, K.B. 1997: A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 24(5): 854-859
Schneider, P.; Visconti, J.A. 1977: Pharmacokinetics in drug therapy III: Clindamycin dosage regimens for treatment of chronic osteomyelitis American Journal of Hospital Pharmacy 34(9): 980-983
Schneider, P.; Visconti, J.A. 1977: Pharmacokinetics in drug therapy Iii: Clindamycin dosage regimens for treatment of chronic osteomyelitis American Journal of Health-System Pharmacy 34(9): 980-983
Gleckman, R.; Gantz, N.M.; Joubert, D.W. 1981: Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions PharmacoTherapy 1(3): 206-211
Gross, R.; Graziani, A.L.; Laufer, D.; Turner, J.L.; Ondercin, J.P.; MacGregor, R.R. 1996: Adverse effects of the use of intravenous pentamidine in the home Infectious Diseases in Clinical Practice 5(7): 456-458
Huang, Y.-H.; Hsin, Y.-C.; Wang, L.-J.; Feng, W.-L.; Guo, M.M.-H.; Chang, L.-S.; Tu, Y.-K.; Kuo, H.-C. 2021: Treatment of Kawasaki Disease: a Network Meta-Analysis of Four Dosage Regimens of Aspirin Combined with Recommended Intravenous Immunoglobulin Frontiers in Pharmacology 12: 725126
Terlinden, R.; Römer, A. 1990: Pharmacokinetics and toxicokinetics of pentamidine in the rat following intravenous and aerosol administration Medizinische Klinik 85(Suppl 2): 245-247
Voehringer, H.F.; Arasteh, K. 1991: Multiple dose pharmacokinetics pk of different dosages intravenous pentamidine Clinical Pharmacology and Therapeutics 49(2): 199
Koppen, S.; Grunewald, T.; Jautzke, G.; Gottschalk, J.; Pohle, H.D.; Ruf, B. 1992: Prevention ofPneumocystis cariniipneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients: a clinical approach comparing aerosolized pentamidine and pyrimethamine/sulfadoxine Journal of Molecular Medicine 70(6): 508-512